NCT05306639

Brief Summary

A prospective randomized trial to study the effect of spinal magnetic stimulation versus posterior tibial neuromodulation in the treatment of monosymptomatic nocturnal enuresis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 13, 2022

Completed
19 days until next milestone

First Posted

Study publicly available on registry

April 1, 2022

Completed
10 months until next milestone

Study Start

First participant enrolled

February 1, 2023

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2023

Completed
Last Updated

January 12, 2023

Status Verified

January 1, 2023

Enrollment Period

4 months

First QC Date

March 13, 2022

Last Update Submit

January 11, 2023

Conditions

Keywords

spinal magnetic stimulation, nocturnal enuresis, neuromodulation

Outcome Measures

Primary Outcomes (2)

  • Frequency of bed wetting

    Number of bed wettings/ week

    one month

  • Visual analogue scale to determine how much the enuresis affected his/her life.

    Visual analogue scale from zero to ten (zero indicates no effect, 10 indicates severe bothersome

    three months

Study Arms (2)

Spinal magnetic stimulation

EXPERIMENTAL

Spinal magnetic stimulation group will receive repetitive spinal magnetic stimulation sessions for a total of 12 sessions. Using the Neuro-MS/D machine, circular coil will be used to stimulate S2,3 and 4 sacral roots. The outer rim of the coil will be positioned in the midline over the sacral vertebrae (approximately 5 cm above the natal cleft, which approximates to the level of S2) Intensities will be adjusted to 50-70 % of maximal output (2.2 Tesla), stimulation frequency will be fixed at 15 Hz, burst length = 10 seconds, inter-burst interval = 30 seconds with a total of 1500 pulses

Other: Rehabilitation

Neuromodulation

EXPERIMENTAL

Neuromodulation group will receive 12 sessions of bilateral transcutaneous posterior tibial neuromodulation using (Myomed 632®, Enraf Nonius, Delft, Netherlands) machine, the active rubber surface was placed behind the medial malleolus and the reference electrode was placed 10 cm proximal. Adjustment of the electric current was as follows: continuous current, pulse duration 200 ms, frequency 20 Hz; each session lasts for 30 min. The current intensity was adjusted according to the tolerance of the patient or until the big toe curls into plantar flexion

Other: Rehabilitation

Interventions

rehabilitation sessions using spinal magnetic stimulation or neuromodulation

NeuromodulationSpinal magnetic stimulation

Eligibility Criteria

Age5 Years - 30 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • All subjects were diagnosed as patients with MNE according to the Diagnostic and statistical manual of mental disorders, 4th revised edition (DSM-IV) (American Psychiatric Association's DSM-IV, 1994): bed-wetting ≥3 times a week; lasting more than 6 months; can control urination during the day but cannot control urination after falling asleep.

You may not qualify if:

  • \- Patients younger than 5 years old.
  • Patients who have any abnormality in blood or urine biochemistry.
  • Patients with other urinary symptoms.
  • Patients with neurological or endocrinal abnormalities (such as cerebral palsy, spinal cord lesion, peripheral neuropathy or diabetes mellitus)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nehad ElShatby

Alexandria, 25700, Egypt

Location

MeSH Terms

Conditions

Nocturnal Enuresis

Interventions

Rehabilitation

Condition Hierarchy (Ancestors)

EnuresisUrination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesBehavioral SymptomsBehaviorElimination DisordersMental Disorders

Intervention Hierarchy (Ancestors)

AftercareContinuity of Patient CarePatient CareTherapeuticsHealth ServicesHealth Care Facilities Workforce and Services

Study Officials

  • Nehad ElShatby

    Alexandria University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Nehad ElShatby

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Physician

Study Record Dates

First Submitted

March 13, 2022

First Posted

April 1, 2022

Study Start

February 1, 2023

Primary Completion

June 1, 2023

Study Completion

July 1, 2023

Last Updated

January 12, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will share

All data will be available with the corresponding author to be shared with other researchers for three years after publishing the study

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
three years after publication
Access Criteria
Researchers can contact the corresponding author directly through e-mail

Locations